Insulet [PODD] vs Edwards Lifesciences [EW] Detailed Stock Comparison

Insulet Corporation

NASDAQ
Loading...

Edwards Lifesciences Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Insulet Corporation wins in 7 metrics, Edwards Lifesciences Corporation wins in 13 metrics, with 0 ties. Edwards Lifesciences Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Insulet Corporation Edwards Lifesciences Corporation Better
P/E Ratio (TTM) 55.27 46.49 Edwards Lifesciences Corporation
Price-to-Book Ratio 8.93 4.73 Edwards Lifesciences Corporation
Debt-to-Equity Ratio 66.18 6.82 Edwards Lifesciences Corporation
PEG Ratio 23.80 -0.62 Insulet Corporation
EV/EBITDA 24.51 23.85 Edwards Lifesciences Corporation
Profit Margin (TTM) 9.12% 17.39% Edwards Lifesciences Corporation
Operating Margin (TTM) 18.67% 31.22% Edwards Lifesciences Corporation
EBITDA Margin (TTM) 18.67% 31.22% Edwards Lifesciences Corporation
Return on Equity 18.12% 10.38% Insulet Corporation
Return on Assets (TTM) 9.43% 7.84% Insulet Corporation
Free Cash Flow (TTM) $349.90M $1.34B Edwards Lifesciences Corporation
1-Year Return -50.86% 13.25% Edwards Lifesciences Corporation
Price-to-Sales Ratio (TTM) 5.00 7.70 Insulet Corporation
Enterprise Value $13.83B $45.35B Edwards Lifesciences Corporation
EV/Revenue Ratio 5.11 7.20 Insulet Corporation
Gross Profit Margin (TTM) 72.54% 78.15% Edwards Lifesciences Corporation
Revenue per Share (TTM) $39 $11 Insulet Corporation
Earnings per Share (Diluted) $3.48 $1.81 Insulet Corporation
Beta (Stock Volatility) 1.47 0.95 Edwards Lifesciences Corporation
Short % of Float 4.97% 1.84% Edwards Lifesciences Corporation

Insulet Corporation vs Edwards Lifesciences Corporation Stock Performance Analysis

Loading Price Chart...

PODD
EW

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Insulet Corporation-1.04%-2.22%0.46%-34.06%-49.18%-47.64%
Edwards Lifesciences Corporation1.37%0.50%6.02%3.26%3.48%1.11%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Insulet Corporation-50.86%-47.38%-46.64%417.99%674.84%886.17%
Edwards Lifesciences Corporation13.25%-7.43%-15.49%159.09%507.93%2,151.59%

Performance & Financial Health Analysis: Insulet Corporation vs Edwards Lifesciences Corporation

MetricPODDEW
Market Information
Market Cap i$13.53B$48.52B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i743,3716,242,650
90 Day Avg. Volume i897,9605,032,270
Last Close$148.14$86.28
52 Week Range$140.63 - $354.88$72.30 - $89.48
% from 52W High-58.26%-3.58%
All-Time High$354.88 (Nov 20, 2025)$131.73 (Dec 27, 2021)
% from All-Time High-58.26%-34.50%
Growth Metrics
Quarterly Revenue Growth0.31%0.17%
Quarterly Earnings Growth0.01%0.06%
Financial Health
Profit Margin (TTM) i0.09%0.17%
Operating Margin (TTM) i0.19%0.31%
Return on Equity (TTM) i0.18%0.10%
Debt to Equity (MRQ) i66.186.82
Cash & Liquidity
Book Value per Share (MRQ)$21.53$17.80
Cash per Share (MRQ)$10.17$7.28
Operating Cash Flow (TTM) i$569.30M$1.50B
Levered Free Cash Flow (TTM) i$154.90M$1.07B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Insulet Corporation vs Edwards Lifesciences Corporation

MetricPODD (Apr 24, 2026)EW (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i55.2746.49
Forward P/E i23.8025.05
PEG Ratio i23.80-0.62
Price to Sales (TTM) i5.007.70
Price to Book (MRQ) i8.934.73
Market Capitalization
Market Capitalization i$13.53B$48.52B
Enterprise Value i$13.83B$45.35B
Enterprise Value Metrics
Enterprise to Revenue i5.117.20
Enterprise to EBITDA i24.5123.85
Risk & Other Metrics
Beta i1.470.95
Book Value per Share (MRQ) i$21.53$17.80

Financial Statements Comparison: Insulet Corporation vs Edwards Lifesciences Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPODD (2025)EW (2025)
Revenue/Sales i2.71B6.07B
Cost of Goods Sold i768.20M1.33B
COGS % of Revenue i28.4%22.0%
Gross Profit i1.94B4.73B
Gross Margin i71.6%78.0%
Research & Development i301.10M1.08B
Operating Income (EBIT) i473.80M1.64B
Operating Margin i17.5%27.0%
EBITDA i600.70M1.96B
EBITDA Margin i22.2%32.4%
Pre-Tax Income i339.50M1.27B
Pre-Tax Income % of Revenue i12.5%21.0%
Income Tax i92.40M216.90M
Income Tax % of Revenue i3.4%3.6%
Net Income (Profit) i247.10M1.07B
Profit Margin i9.1%17.6%

Balance Sheet & Liquidity Metrics

MetricPODD (2025)EW (2025)
Cash & Equivalents i716.10M2.94B
Total Current Assets i1.91B6.74B
Total Current Assets % of Revenue i70.7%111.1%
Total Current Liabilities i680.10M1.81B
Total Current Liabilities % of Revenue i25.1%29.9%
Long-Term Debt i930.80M680.90M
Long-Term Debt % of Revenue i34.4%11.2%
Total Shareholders Equity i1.52B10.34B
Retained Earnings i287.40M14.24B
Retained Earnings % of Revenue i10.6%234.7%
Property, Plant & Equipment i0102.70M

Cash Flow Statement Comparison

MetricPODD (2025)EW (2025)
Operating Cash Flow i374.00M1.50B
Operating Cash Flow % of Revenue i13.8%24.7%
Capital Expenditures iN/AN/A
Free Cash Flow i349.90M1.34B
FCF Margin i12.9%22.0%
Debt Repayment i-1.21BN/A
Common Stock Repurchase i-59.60M-893.40M

Short Interest & Institutional Ownership Analysis

MetricPODDEW
Shares Short i3.05M9.33M
Short Ratio i3.132.05
Short % of Float i4.97%1.84%
Shares Outstanding i70.39M580.70M
Float Shares i70.10M579.02M
% Held by Insiders i0.31%0.17%
% Held by Institutions i105.62%92.88%
% Held by Public i-5.93%6.95%

Dividend Analysis & Yield Comparison: Insulet Corporation vs Edwards Lifesciences Corporation

MetricPODDEW
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A